Orgenesis (STU:45O0) Cyclically Adjusted PS Ratio: (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:45O0 Orgenesis Inc STU:45O0
12 GF Score
Price €3.40
View Full Analysis

What is Orgenesis Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Orgenesis  (STU:45O0) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Orgenesis Cyclically Adjusted PS Ratio Related Terms


Orgenesis Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Orgenesis's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis Cyclically Adjusted PS Ratio Chart

Orgenesis Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.13 3.23 1.93 0.54 0.00

Orgenesis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 0.89 0.67 0.51 0.00

STU:45O0 vs ENDV, GBLX, OMGAQ: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Orgenesis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Orgenesis's Cyclically Adjusted PS Ratio falls into.


STU:45O0
12GF Score
Orgenesis Inc STU:45O0
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orgenesis Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Orgenesis's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Orgenesis's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.057/315.6050*315.6050
=0.057

Current CPI (Dec. 2024) = 315.6050.

Orgenesis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201502 0.000 234.722 0.000
201505 1.403 237.805 1.862
201508 1.789 238.316 2.369
201511 2.428 237.336 3.229
201602 1.596 237.111 2.124
201605 1.116 240.229 1.466
201608 1.779 240.849 2.331
201611 2.552 241.353 3.337
201702 1.872 243.603 2.425
201705 2.173 244.733 2.802
201708 2.089 245.519 2.685
201711 2.780 246.669 3.557
201802 1.981 248.991 2.511
201805 2.567 251.588 3.220
201808 3.757 252.146 4.703
201811 3.366 252.038 4.215
201903 4.150 254.202 5.152
201906 0.626 256.143 0.771
201909 5.167 256.759 6.351
201912 -11.365 256.974 -13.958
202003 0.956 258.115 1.169
202006 0.722 257.797 0.884
202009 0.665 260.280 0.806
202012 0.791 260.474 0.958
202103 3.260 264.877 3.884
202106 3.591 271.696 4.171
202109 3.037 274.310 3.494
202112 2.514 278.802 2.846
202203 2.662 287.504 2.922
202206 2.745 296.311 2.924
202209 3.176 296.808 3.377
202212 5.034 296.797 5.353
202303 0.050 301.836 0.052
202306 0.036 305.109 0.037
202309 0.034 307.789 0.035
202312 0.050 306.746 0.051
202403 0.039 312.332 0.039
202406 0.059 314.175 0.059
202409 0.066 315.301 0.066
202412 0.057 315.605 0.057

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Orgenesis Business Description

Address 20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies. The company's therapies pipeline includes Immuno-Oncology, Viral Diseases, Metabolic & Autoimmune Diseases, Vascular & Musculoskeletal Diseases, and Kidney Disease.
12GF Score

Get the complete analysis for STU:45O0

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.40
Price